S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Gritstone bio Stock Forecast, Price & News

+0.28 (+2.58%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
565,800 shs
Average Volume
1.49 million shs
Market Capitalization
$756.03 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive GRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

Gritstone bio logo

About Gritstone bio

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$4.04 million
Book Value
$3.06 per share


Net Income
$-105.31 million
Net Margins
Pretax Margin




Free Float
Market Cap
$756.03 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.40 out of 5 stars

Medical Sector

179th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

26th out of 201 stocks

Analyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Gritstone bio (NASDAQ:GRTS) Frequently Asked Questions

Is Gritstone bio a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Gritstone bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTS, but not buy additional shares or sell existing shares.
View analyst ratings for Gritstone bio
or view top-rated stocks.

How has Gritstone bio's stock been impacted by Coronavirus?

Gritstone bio's stock was trading at $6.67 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GRTS stock has increased by 66.7% and is now trading at $11.12.
View which stocks have been most impacted by COVID-19

Are investors shorting Gritstone bio?

Gritstone bio saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 2,080,000 shares, an increase of 18.9% from the October 14th total of 1,750,000 shares. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is presently 2.0 days.
View Gritstone bio's Short Interest

When is Gritstone bio's next earnings date?

Gritstone bio is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Gritstone bio

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.16. Gritstone bio had a negative trailing twelve-month return on equity of 38.51% and a negative net margin of 155.88%.
View Gritstone bio's earnings history

What price target have analysts set for GRTS?

3 brokerages have issued twelve-month target prices for Gritstone bio's stock. Their forecasts range from $8.00 to $35.00. On average, they expect Gritstone bio's stock price to reach $22.33 in the next twelve months. This suggests a possible upside of 100.8% from the stock's current price.
View analysts' price targets for Gritstone bio
or view top-rated stocks among Wall Street analysts.

Who are Gritstone bio's key executives?

Gritstone bio's management team includes the following people:
  • Andrew R. Allen, President, Chief Executive Officer & Director
  • Erin E. Jones, Chief Operating Officer (LinkedIn Profile)
  • Vassiliki Celia Economides, Chief Financial Officer & Executive Vice President
  • Karin Jooss, Head-Research & Development
  • Raphaël Rousseau, Chief Medical Officer & Executive Vice President

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio CEO Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among Gritstone bio's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

When did Gritstone bio IPO?

(GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone bio's stock symbol?

Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS."

Who are Gritstone bio's major shareholders?

Gritstone bio's stock is owned by many different retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (8.18%), Versant Venture Management LLC (8.10%), BlackRock Inc. (6.42%), BVF Inc. IL (3.09%), Geode Capital Management LLC (1.43%) and Invesco Ltd. (0.84%). Company insiders that own Gritstone bio stock include Erin Jones and Raphael Rousseau.
View institutional ownership trends for Gritstone bio

Which major investors are selling Gritstone bio stock?

GRTS stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Versant Venture Management LLC, BVF Inc. IL, Ensign Peak Advisors Inc, Two Sigma Advisers LP, Russell Investments Group Ltd., Marshall Wace LLP, and Dimensional Fund Advisors LP. Company insiders that have sold Gritstone bio company stock in the last year include Erin Jones, and Raphael Rousseau.
View insider buying and selling activity for Gritstone bio
or view top insider-selling stocks.

Which major investors are buying Gritstone bio stock?

GRTS stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BlackRock Inc., Invesco Ltd., Geode Capital Management LLC, Jane Street Group LLC, Citadel Advisors LLC, UBS Group AG, and DG Capital Management LLC.
View insider buying and selling activity for Gritstone bio
or or view top insider-buying stocks.

How do I buy shares of Gritstone bio?

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gritstone bio's stock price today?

One share of GRTS stock can currently be purchased for approximately $11.12.

How much money does Gritstone bio make?

Gritstone bio has a market capitalization of $756.03 million and generates $4.04 million in revenue each year. The company earns $-105.31 million in net income (profit) each year or ($1.28) on an earnings per share basis.

How many employees does Gritstone bio have?

Gritstone bio employs 169 workers across the globe.

What is Gritstone bio's official website?

The official website for Gritstone bio is www.gritstoneoncology.com.

Where are Gritstone bio's headquarters?

Gritstone bio is headquartered at 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608.

How can I contact Gritstone bio?

Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at (510) 871-6100 or via email at [email protected].

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.